Home
Drugs
Atezolizumab
Clinical Trials

Clinical Trials Related to Atezolizumab

Related studies linked through entity extraction aliases.

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Status: RECRUITING
Phase: PHASE2/PHASE3

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Status: RECRUITING
Phase: PHASE1/PHASE2

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Status: TERMINATED
Phase: PHASE2

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Status: TERMINATED
Phase: PHASE2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Status: RECRUITING
Phase: PHASE2

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Status: RECRUITING
Phase: PHASE2/PHASE3

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Status: TERMINATED
Phase: PHASE4

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

Status: NOT_YET_RECRUITING
Phase: PHASE2

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Status: RECRUITING
Phase: PHASE1/PHASE2

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE4

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Status: RECRUITING
Phase: PHASE2

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Status: RECRUITING
Phase: PHASE1/PHASE2

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Status: RECRUITING
Phase: PHASE1

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Status: WITHDRAWN
Phase: PHASE2

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Status: RECRUITING
Phase: PHASE1

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Status: RECRUITING
Phase: PHASE2